BR112021021015A2 - Mistura de nutrientes à base de triglicerídeos de cadeia média (tcm) para fornecer benefícios de saúde a animais - Google Patents

Mistura de nutrientes à base de triglicerídeos de cadeia média (tcm) para fornecer benefícios de saúde a animais

Info

Publication number
BR112021021015A2
BR112021021015A2 BR112021021015A BR112021021015A BR112021021015A2 BR 112021021015 A2 BR112021021015 A2 BR 112021021015A2 BR 112021021015 A BR112021021015 A BR 112021021015A BR 112021021015 A BR112021021015 A BR 112021021015A BR 112021021015 A2 BR112021021015 A2 BR 112021021015A2
Authority
BR
Brazil
Prior art keywords
animals
health benefits
provide health
medium
mct
Prior art date
Application number
BR112021021015A
Other languages
English (en)
Inventor
Yuanlong Pan
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of BR112021021015A2 publication Critical patent/BR112021021015A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/42—Dry feed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Feed For Specific Animals (AREA)

Abstract

mistura de nutrientes à base de triglicerídeos de cadeia média (tcm) para forncer beneficíos de saúde a animais. a presente invenção refere-se a um método para tratar sarcopenia ou atrofia muscular em um animal e um método para aumentar o ganho de peso, aumentar o ganho de gordura ou manter a massa corporal magra em um animal que precise desse tratamento. o método pode compreender a administração oral de uma composição que compreende uma quantidade terapeuticamente eficaz de triglicerídeos de cadeia média ao animal.
BR112021021015A 2019-05-31 2020-05-29 Mistura de nutrientes à base de triglicerídeos de cadeia média (tcm) para fornecer benefícios de saúde a animais BR112021021015A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855045P 2019-05-31 2019-05-31
PCT/IB2020/055123 WO2020240500A1 (en) 2019-05-31 2020-05-29 Mct-based nutrition blend for providing health benefits in animals

Publications (1)

Publication Number Publication Date
BR112021021015A2 true BR112021021015A2 (pt) 2021-12-14

Family

ID=70977553

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021015A BR112021021015A2 (pt) 2019-05-31 2020-05-29 Mistura de nutrientes à base de triglicerídeos de cadeia média (tcm) para fornecer benefícios de saúde a animais

Country Status (9)

Country Link
US (1) US20200375937A1 (pt)
EP (1) EP3934441A1 (pt)
JP (1) JP2022534471A (pt)
CN (1) CN113840536A (pt)
AU (1) AU2020284169A1 (pt)
BR (1) BR112021021015A2 (pt)
CA (1) CA3140992A1 (pt)
MX (1) MX2021013777A (pt)
WO (1) WO2020240500A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024068809A1 (en) * 2022-09-30 2024-04-04 Société des Produits Nestlé S.A. Composition and method for treating muscle decline associated with renal disease or dysfunction
WO2024069273A1 (en) * 2022-09-30 2024-04-04 Societe Des Produits Nestle Sa Methods for providing health benefits in animals
WO2024068808A1 (en) * 2022-09-30 2024-04-04 Société des Produits Nestlé S.A. Composition and method for treating muscle decline associated with renal disease or dysfunction

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1090636A1 (en) * 1999-09-13 2001-04-11 Société des Produits Nestlé S.A. High lipid diet
FR2827518B1 (fr) 2001-07-17 2005-07-08 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie
US20060003959A1 (en) 2004-06-10 2006-01-05 Steven Burden Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same
EP1855694B1 (en) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
EP2001475B1 (en) 2006-03-15 2018-11-14 Michael O. Thorner Methods for treating sarcopenia with a growth hormone secretagogue
WO2011078654A1 (en) * 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
BR112013019677B1 (pt) * 2011-02-02 2019-10-08 Société des Produits Nestlé S.A. Uso de proteína compreendendo pelo menos 30% do total da energia da composição nutricional e de uma proporção de ácidos graxos ômega-6 e ômega-3
WO2012143405A1 (en) * 2011-04-18 2012-10-26 Nestec S.A. Nutritional compositions having alpha-hica and alpha-ketoglutarate
CN102488088A (zh) * 2011-11-14 2012-06-13 龙岩新奥生物科技有限公司 中链脂肪酸甘油酯及其在微胶囊中的应用
CA2883191C (en) * 2012-08-23 2021-06-22 Nestec S.A. Managing weight loss and body mass
WO2014098193A1 (ja) * 2012-12-19 2014-06-26 花王株式会社 ペットフード
BR112017007066A2 (pt) * 2014-10-10 2017-12-12 Nestec Sa composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade
EP3458046B1 (en) * 2016-05-20 2021-01-13 Société des Produits Nestlé S.A. Medium-chain triglycerides for the treatment of degenerative mitral valve disease in companion animals
EP3711493A1 (en) * 2016-11-16 2020-09-23 Fresenius Kabi Deutschland GmbH Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients
WO2019092570A1 (en) * 2017-11-09 2019-05-16 Nestec Sa Nutrition blend for health benefits in animals

Also Published As

Publication number Publication date
JP2022534471A (ja) 2022-08-01
CN113840536A (zh) 2021-12-24
AU2020284169A1 (en) 2021-10-28
CA3140992A1 (en) 2020-12-03
WO2020240500A1 (en) 2020-12-03
US20200375937A1 (en) 2020-12-03
EP3934441A1 (en) 2022-01-12
MX2021013777A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
BR112021021015A2 (pt) Mistura de nutrientes à base de triglicerídeos de cadeia média (tcm) para fornecer benefícios de saúde a animais
Konrad et al. Effect of PNF stretching training on the properties of human muscle and tendon structures
Mickleborough et al. The effects PCSO-524®, a patented marine oil lipid and omega-3 PUFA blend derived from the New Zealand green lipped mussel (Perna canaliculus), on indirect markers of muscle damage and inflammation after muscle damaging exercise in untrained men: a randomized, placebo controlled trial
Ranjbar et al. Combined exercise training positively affects muscle wasting in tumor-bearing mice
BR112018072064B8 (pt) Uso de triglicerídeos de cadeia média para preparação de composições nutricionais para proteção cardíaca em animais de estimação
BR112012015961A2 (pt) composições incluindo piruvato para animais de estimação e métodos de uso dos mesmos
BRPI0819451A2 (pt) Composição farmacêutica, método para tratar dor, kit farmacêutico, e, uso de uma composição
BRPI0819690B8 (pt) uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas
KR101559515B1 (ko) 기능성 사료 첨가제 조성물
BR112013018839A2 (pt) métodos e composições para o tratamento, a redução ou a prevenção de deterioração do sistema visual dos animais
Binns et al. Changes in lean mass and serum myostatin with habitual protein intake and high-velocity resistance training
MX2017004662A (es) Composiciones y metodos para mejorar la movilidad o actividad o tratar la fragilidad.
Duff et al. Effects of ibuprofen and resistance training on bone and muscle: An RCT in older women
MX2020011923A (es) Metodos y composiciones para incrementar los cuerpos cetonicos en animales.
BR112023001143A2 (pt) Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo
BR112022014911A2 (pt) Composição de saúde articular e uso da mesma em mamíferos saudáveis
BRPI0513953A (pt) métodos para tratamento de doenças ou distúrbios mediados pela ccr2
Etesami et al. Comparison of the effect of 8 weeks of land exercise therapy and hydrotherapy on functional activities of elderly women with knee osteoarthritis
Arora et al. Effect of 12-weeks of aerobic exercise on primary dysmennorrhea
Ramzan The racehorse: A veterinary manual
BR112021021774A2 (pt) Blenda de nutrientes à base de mct para fornecer benefícios de saúde a animais
Lima et al. Contralateral botulinum toxin improved functional recovery after tibial nerve repair in rats
Widodo et al. Herbs as A Feed Additive in the Broilers for the Sustainability of Local Products
Panthukumphol Onset and stages of anesthesia in Nile tilapia (Oreochromis niloticus) at different concentration of eugenol.
Prajapati et al. Effectiveness of Mobilization versus Modified Cross Body Stretch in Posterior Shoulder Tightness in Pace Bowlers